Search
Dasatinib
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint clust...
Dasatinib Inhibition of BCR-ABL
smpdb.ca/view/SMP0123165Drug actionDasatinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. … Dasatinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation
Drugs: BafetinibDasatinib Inhibition of BCR-ABL Action Pathway
smpdb.ca/view/SMP0031696Drug actionNotably, Dasatinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary. … Dasatinib is able to bind ABL with greater affinity than Imatinib, partly owing to its ability to recognize multiple states of the enzyme.
Drugs: DasatinibBlast phase Chronic myeloid leukemia
go.drugbank.com/conditions/DBCOND0023499Chronic Phase Chronic Myeloid Leukemia
go.drugbank.com/conditions/DBCOND0057382Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigationalExisting inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those
Acute Lymphoblastic Leukemia (ALL)
go.drugbank.com/conditions/DBCOND0031335Drugs: Asparaginase Erwinia chrysanthemi · Asparaginase Escherichia coli · Calaspargase pegol · Cyclophosphamide · Dasatinib · Daunorubicin +6 moreBosutinib Inhibition of BCR-ABL Action Pathway
smpdb.ca/view/SMP0031698Drug actionBosutinib may have a safer toxicity profile than both Imatinib and Dasatinib because it does not significantly inhibit the receptors KIT and PDGFR.
Drugs: Bosutinib